Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05045950 · ClinicalTrials.gov registry record · Phase 2
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
A Phase 2 study of Brain Metastases, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 2
- Study locations
NCT05045950: Recruiting Phase 2 study of Brain Metastases, sponsored by Medical College of Wisconsin.
NCT05045950 is a Phase 2 study of Brain Metastases that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 53 participants, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05045950, a Phase 2 study of Brain Metastases, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 2
- Study locations
Study Summary
Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
Primary Outcome
The number of subjects successfully completing PRDR WBRT treatment within five days of intended treatment completion.
Conditions Studied
Interventions
- DRUG Memantine -Twice Daily or Extended Release
- RADIATION WBRT utilizing the PRDR technique
Study Locations (2)
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
- Clement J. Zablocki Veterans Affairs Medical Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
What NCT05045950 shows while recruiting
NCT05045950 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 212-participant average among 67 other Brain Metastases trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Memantine -Twice Daily or Extended Release is the first listed.
NCT05045950 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05045950 about?
NCT05045950 is a clinical study titled "Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique". Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
What is the current status of trial NCT05045950?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2021-11-17. Estimated completion is 2029-05.
What conditions does trial NCT05045950 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT05045950?
The interventions under investigation include: Memantine -Twice Daily or Extended Release (DRUG), WBRT utilizing the PRDR technique (RADIATION).
Who is sponsoring clinical trial NCT05045950?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05045950 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05045950's enrollment target sits among peer trials
53 26th of 67 higher than 42 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI